IPG Health has launched what it is calling an industry-first offering designed to help pharma and healthcare companies diversify their clinical trials and ensure more inclusive treatment innovations.
According to the firm, main obstacles to more diversified trials revolve around outreach and recruitment issues. The agency says it can overcome these obstacles by leveraging data analytics, patient experience insights and other techniques to better understand patient behaviors and create more effective engagement strategies.
IPG Health CEO, Dana Maiman said the firm’s new clinical trial diversity offering “is a pivotal move in helping clients unlock new opportunities and address significant unmet needs in underserved populations and, ultimately, helping to accelerate equity in healthcare.”
The new offering is an extension of IPG Health’s EDI (Equity, Diversity, Inclusion) +You strategy, which includes “inQ” (Inclusion Intelligence Quotient) — a proprietary strategic framework designed to ensure more inclusive experiences and creative solutions across the network’s 45-plus agencies.
The agency says the framework is inspired by the World Health Organization’s Determinants Of Health model and focuses on understanding howmultiple factors and influences impact exclusion or inclusion of people so that no populations are left behind.